

CERTIFICATION OF MAILING BY "EXPRESS MAIL"

Express Mail Label No. EH 336 000 059 US

Date of Deposit: 8 January 2001



Stephen C. Macevitz

I hereby certify that this paper or fee and accompanying documents referred to below are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Assistant Commissioner of Patents, Washington, D.C. 20231

ENZYMATIC SYNTHESIS OF OLIGONUCLEOTIDE TAGS

5

Field of the Invention

The invention relates generally to methods for synthesizing collections of minimally cross-hybridizing oligonucleotide tags for identifying, sorting, and/or tracking molecules, especially polynucleotides.

10

BACKGROUND

Specific hybridization of oligonucleotides and their analogs is a fundamental process that is employed in a wide variety of research, medical, and industrial applications, including the identification of disease-related polynucleotides in diagnostic assays, screening for clones of novel target polynucleotides, identification of specific polynucleotides in blots of mixtures of polynucleotides, amplification of specific target polynucleotides, therapeutic blocking of inappropriately expressed genes, DNA sequencing, and the like, e.g. Sambrook et al, Molecular Cloning: A Laboratory Manual, 2nd Edition (Cold Spring Harbor Laboratory, New York, 1989); Keller and Manak, DNA Probes, 2nd Edition (Stockton Press, New York, 1993); Milligan et al, J. Med. Chem., 36: 1923-1937 (1993); Drmanac et al, Science, 260: 1649-1652 (1993); Bains, J. DNA Sequencing and Mapping, 4: 143-150 (1993).

15

20

Specific hybridization has also been proposed as a method of tracking, retrieving, and identifying compounds labeled with oligonucleotide tags, e.g. Brenner, International application PCT/US95/12791; Church et al, Science, 240: 185-188 (1988); Brenner and Lerner, Proc. Natl. Acad. Sci., 89: 5381-5383 (1992); Alper, Science, 264: 1399-1401 (1994); Cheverin et al, Biotechnology, 12: 1093-1099 (1994); and Needels et al, Proc. Natl. Acad. Sci., 90: 10700-10704 (1993). The successful implementation of such tagging and sorting schemes depends in large part on the success in achieving specific hybridization between a tag and its complement. That is, for an oligonucleotide tag to successfully identify a substance, the number of false positive and false negative signals brought about by incorrect hybridizations must be minimized. And for oligonucleotide tags to effectively sort molecules, the number of tags hybridized to complements at incorrect sites must be minimized. Unfortunately, incorrect hybridizations brought about by the

25

30

creation of stable duplexes containing mismatches are not uncommon because base pairing and base stacking free energies vary widely among nucleotides in a duplex or triplex structure. For example, a duplex consisting of a repeated sequence of deoxyadenosine (A) and thymidine (T) bound to its complement may have less stability than an equal-length duplex consisting of a repeated sequence of deoxyguanosine (G) and deoxycytidine (C) bound to a partially complementary target containing a mismatch. Thus, if a desired compound from a large combinatorial chemical library were tagged with the former oligonucleotide, a significant possibility would exist that, under hybridization conditions designed to detect perfectly matched AT-rich duplexes, undesired compounds labeled with the GC-rich oligonucleotide--even in a mismatched duplex--would be detected or sorted along with the perfectly matched duplexes consisting of the AT-rich tag. Even though reagents, such as tetramethylammonium chloride, are available to negate base-specific stability differences of oligonucleotide duplexes, the effect of such reagents is often limited and their presence can be incompatible with, or render more difficult, further manipulations of the selected compounds, e.g. amplification by polymerase chain reaction (PCR), or the like.

Such problems have been addressed in the "solid phase" cloning technique, described in Brenner, International application PCT/US95/12791, by the development of oligonucleotide tags synthesized combinatorially from a set of so-called minimally cross-hybridizing oligonucleotides, or "words." The words, which are oligonucleotides usually 3 to 6 nucleotides in length, differ from every other member of the same set by at least two nucleotides. Thus, a given word cannot form a duplex with the complement of any other word of the set without less than two mismatches. Of course, minimally cross-hybridizing sets are preferably formed from words differing from one another by even more than two nucleotides.

In such a scheme, different oligonucleotide tags constructed from concatenations of such words will differ from one another by at least two nucleotides, or by at least the number of nucleotides that their component words differ by. Therefore, by judiciously selecting word length, differences between words in a set, and the number of words per tag, one can obtain a large set, or repertoire, of oligonucleotide tags that each differ from one another by a significant percentage of their nucleotides. Such repertoires permit tagging and sorting of molecules with a much higher degree of specificity than ordinary oligonucleotides.

Unfortunately, current methods of solid phase synthesis, although highly efficient, still lead to a significant fraction of failure sequences when oligonucleotide tags start to exceed 30 to 40 nucleotides in length. The presence of such failure sequences can have a significant impact on solid phase cloning and sorting schemes, such as the one described in Brenner (cited above).

When tag complements are synthesized separately from their corresponding oligonucleotide tags,

the presence of different sets of failure sequences among the two reaction products means that not every oligonucleotide from one reaction will necessarily have a complementary oligonucleotide among products of the other reaction. In particular, failure sequences produced in one reaction will generally not have complementary failure sequences produced in the other reaction. While this is not a problem for tag complements combinatorially synthesized on solid phase supports because the number and kind of failures are randomly distributed among a population of predominantly correct-sequence oligonucleotides, for tags attached to DNAs which are sampled and amplified, a significant probability exists that if one or more of the sampled tags contain failure sequences, no solid phase supports will exist for them that has a population of perfect complements. Consequently, DNAs with such tags cannot be effectively sorted.

In view of the above, it would be useful if there were available a method of producing oligonucleotide tags which would avoid or minimize the chance of there being sampled and amplified tags that contain failure sequences.

Summary of the Invention

Accordingly, objectives of my invention include, but are not limited to, providing a method of synthesizing oligonucleotide tags which minimizes the production of failure sequences; providing an enzymatic method of synthesizing oligonucleotide tags by the combinatorial addition of words; providing a method of convergent synthesis of oligonucleotide tags from error-free components; providing a method of constructing tag-DNA conjugates whose tags are free of failure sequences; providing compositions comprising novel oligonucleotide tags.

My invention achieves these and other objectives by providing a method of synthesizing oligonucleotide tags that comprises successive cycles of cleavage of a oligonucleotide tag precursor to permit the ligation of one or more words from a minimally cross-hybridizing set, ligation of the one or more words, and amplification of ligated structure. Preferably, repertoires of oligonucleotide tags of a predetermined length are assembled from words, or sub-assemblies of words, that are free of failure sequences. Preferably, such error-free words or sub-assemblies of words are obtained either by separately synthesizing and sequencing individual words or sub-assemblies of words prior to assembly, or by successive ligations of adaptors having protruding strands consisting of word sequences that select complementary word sequences on the protruding strand of a growing tag. Preferably, in the former embodiment, words or sub-assemblies of words are inserted into and maintained in conventional cloning vectors, after which they are sequenced to confirm that no errors are present. For use in the method of the invention, the words or sub-assemblies of words are excised from the vectors, mixed, and ligated to an oligonucleotide tag precursor. Preferably, in the latter embodiment, error-containing words are excluded from the

assembly process by requiring that the single stranded form of each added word anneal to a perfectly matched complement of an oligonucleotide tag precursor in a ligation step. If a mismatch exists because a failure sequence is present in one of the strands, no ligation will take place, either precluding further growth of the tag if the failure is carried by its protruding strand, or promoting the annealing of a different word if the failure is carried by the word being added.

The invention further includes repertoires of oligonucleotide tags consisting of a plurality of words wherein at least two words of the plurality are separated by one or two nucleotides.

The present invention overcomes difficulties in sorting polynucleotides with oligonucleotide tags synthesized by currently available methods. By providing oligonucleotide tags free of failure sequences, sampled and amplified tag-polynucleotide conjugates are assured of finding a tag complement with which to form a perfectly matched duplex.

Brief Description of the Drawings

Figure 1a illustrates a preferred embodiment of the invention in which oligonucleotide tags are assembled by successive additions of one or more words to an oligonucleotide tag precursor.

Figure 1b illustrates a preferred embodiment of the invention in which oligonucleotide tags are assembled by convergent additions of increasingly larger sub-assemblies of words.

Figure 2 illustrates a preferred embodiment of the invention wherein oligonucleotide tags are assembled by successive additions and self-selection of words to an oligonucleotide tag precursor.

Definitions

As used herein, the term "word" means an oligonucleotide selected from a minimally cross-hybridizing set of oligonucleotides, as disclosed in U.S. patent 5,604,097; International patent application PCT/US96/09513; and allowed U.S. patent application Ser. No. 08/659,453; which references are incorporated by reference. An oligonucleotide tag of the invention consists of a plurality of words, or oligonucleotide subunits, that are selected from the same minimally cross-hybridizing set. In such a set, a duplex or triplex consisting of a word of the set and the complement of any other word of the same set contains at least two mismatches. Preferably, a duplex or triplex consisting of a word of the set and the complement of any other word of the same set contains an even larger minimum number of mismatches, e.g. 3, 4, 5, or 6, depending on the length of the words. Still more preferably, the minimum number of mismatches is either 1, 2, or 3 less than the length of the word. Most preferably, the minimum number of mismatches is 1 or 2 less than the length of the word.

"Complement" or "tag complement" as used herein in reference to oligonucleotide tags refers to an oligonucleotide to which a oligonucleotide tag specifically hybridizes to form a perfectly matched duplex or triplex. In embodiments where specific hybridization results in a triplex, the oligonucleotide tag may be selected to be either double stranded or single stranded.

Thus, where triplexes are formed, the term "complement" is meant to encompass either a double stranded complement of a single stranded oligonucleotide tag or a single stranded complement of a double stranded oligonucleotide tag. Usually, populations of identical tag complements are attached to a spatially defined region of a solid phase support. Preferably, such solid phase supports are microparticles and the defined region is the entire surface of the microparticle.

The term "oligonucleotide" as used herein includes linear oligomers of natural or modified monomers or linkages, including deoxyribonucleosides, ribonucleosides, anomeric forms thereof, peptide nucleic acids (PNAs), and the like, capable of specifically binding to a target polynucleotide by way of a regular pattern of monomer-to-monomer interactions, such as Watson-Crick type of base pairing, base stacking, Hoogsteen or reverse Hoogsteen types of base pairing, or the like. Usually monomers are linked by phosphodiester bonds or analogs thereof to form oligonucleotides ranging in size from a few monomeric units, e.g. 3-4, to several tens of monomeric units. Whenever an oligonucleotide is represented by a sequence of letters, such as "ATGCCTG," it will be understood that the nucleotides are in 5'→3' order from left to right and that upper or lower case "A" denotes deoxyadenosine, upper or lower case "C" denotes deoxycytidine, upper or lower case "G" denotes deoxyguanosine, and upper or lower case "T" denotes thymidine, unless otherwise noted. Analogs of phosphodiester linkages include phosphorothioate, phosphorodithioate, phosphoranilidate, phosphoramidate, and the like. Usually oligonucleotides of the invention comprise the four natural nucleotides; however, they may also comprise non-natural nucleotide analogs. It is clear to those skilled in the art when oligonucleotides having natural or non-natural nucleotides may be employed, e.g. where processing by enzymes is called for, usually oligonucleotides consisting of natural nucleotides are required.

"Perfectly matched" in reference to a duplex means that the poly- or oligonucleotide strands making up the duplex form a double stranded structure with one other such that every nucleotide in each strand undergoes Watson-Crick basepairing with a nucleotide in the other strand. The term also comprehends the pairing of nucleoside analogs, such as deoxyinosine, nucleosides with 2-aminopurine bases, and the like, that may be employed. In reference to a triplex, the term means that the triplex consists of a perfectly matched duplex and a third strand in which every nucleotide undergoes Hoogsteen or reverse Hoogsteen association with a basepair of the perfectly matched duplex. Conversely, a "mismatch" in a duplex between a tag and an

oligonucleotide means that a pair or triplet of nucleotides in the duplex or triplex fails to undergo Watson-Crick and/or Hoogsteen and/or reverse Hoogsteen bonding.

As used herein, the term "complexity" in reference to a population of polynucleotides means the number of different species of molecule present in the population.

As used herein, the term "failure sequence" refers to a synthetic oligonucleotide or polynucleotide that does not have the correct, or intended, length and/or sequence because of a failure in a step of the synthetic process, e.g. spurious chain initiation, failure of a coupling step, failure of a capping step, chain scission, or the like.

As used herein, "amplicon" means the product of an amplification reaction. That is, it is a population of polynucleotides, usually double stranded, that are replicated from a few starting sequences. Preferably, amplicons are produced either in a polymerase chain reaction (PCR) or by replication in a cloning vector.

Detailed Description of the Invention

The invention provides an enzymatic method for synthesizing a repertoire of oligonucleotide tags whose members are substantially free of failure sequences. Oligonucleotide tags are combinatorially synthesized by the assembly of error-free words or sub-assemblies of words in a series of enzymatic steps. Generally, the method of the invention comprises the following steps: (a) providing a repertoire of oligonucleotide tag precursors in an amplicon, the oligonucleotide tag precursors each comprising one or more words, and each of the one or more words being selected from the same minimally cross-hybridizing set; (b) cleaving the amplicon at a word in each of the oligonucleotide tag precursors to form one or more ligatable ends on each oligonucleotide tag precursor; (c) ligating one or more words to the one or more ligatable ends to elongate each of the oligonucleotide tag precursors; (d) amplifying the elongated oligonucleotide tag precursors in the amplicon; and (e) repeating steps (b) through (d) until a repertoire of oligonucleotide tags having the predetermined length is formed. The repertoire of oligonucleotide tags of the desired length contained in the final amplicon may then be inserted into a convenient cloning vector, as taught by Brenner et al, International patent application PCT/US96/09513. Preferably, each of the oligonucleotide tag precursors has the same length, which is determined by word length, the number of words making up the initial oligonucleotide tag precursor, and the stage of the assembly process, i.e. how many words or sub-assemblies of words have been added by operation of the method of the invention. Preferably, the amplicon of the method is a population of cloning vectors wherein different oligonucleotide tags or oligonucleotide tag precursors are represented in equal proportions as inserts of such vectors. Preferably, whenever the oligonucleotide tag precursors are cleaved for the ligation of an additional word or sub-

assembly of words, the cleavage takes place at the same word for all the oligonucleotide tag precursors of the repertoire. Preferably, the step of cleaving is carried out with a type II_S restriction endonuclease which cleaves at the same word for all the oligonucleotide tag precursors of the repertoire and produces ligatable ends having protruding strands. As used herein, the term "ligatable ends" means ends of a double stranded DNA that can be ligated to another double stranded DNA, including blunt-end ligation and "sticky" end ligation. Preferably, ligatable ends are sticky ends.

The invention further includes repertoires of oligonucleotide tags defined by the following formula.

10

$$w_1(N)_{x_1}w_2(N)_{x_2} \dots (N)_{x_{n-1}}w_n$$

wherein w_1, w_2, \dots, w_n are words selected from the same minimally cross-hybridizing set, the words having a length of from three to fourteen nucleotides or basepairs; n is an integer in the range of from 4 to 10; N is a nucleotide or basepair; and x_1, x_2, \dots, x_{n-1} are each an integer indicating how many nucleotides or basepairs, N , are present at the given location in the sequence of words, x_1, x_2, \dots, x_{n-1} each being selected from the group consisting of 0, 1, 2, 3, and 4, provided that at least one of x_1, x_2, \dots, x_{n-1} is 1, 2, 3, or 4. Preferably, x_1, x_2, \dots, x_{n-1} are each selected from the group consisting of 0, 1, and 2, provided that at least one of x_1, x_2, \dots, x_{n-1} is 1 or 2. Preferably, oligonucleotide tags of the above formula are synthesized by the method of the invention.

Preferably, words are from three to fourteen nucleotides or basepairs in length; and more preferably, words are from four to six nucleotides or basepairs in length. Most preferably, words are four nucleotides or basepairs in length. Usually, words consist of a linear sequence of nucleotides selected from the group consisting of A, C, G, and T. For words constructed from 3 of the 4 natural nucleotides, the following word sizes, differences between words of the same set, and set sizes are preferred.

Word Length	Difference Between Words	Set Size
4	3	8
5	4	6
6	4	9
7	5	8
8	5	16
8	6	9

In some embodiments employing words of the above characteristics, subsets of the computed sets may be employed so that only words having specified GC content, melting temperature, reduced likelihood of self annealing, hairpin formation, or the like, are used to form tags. The above set sizes were computed using the algorithms listed in Brenner et al, PCT/US96/09513 and allowed

5 U.S. patent application Ser. No. 08/659,453. Exemplary minimally cross-hybridizing sets of words for use with the invention are listed in the following table:

Table I

10 Exemplary Sets of Minimally Cross-Hybridizing Words

Number of Nucleotides per Word (Minimal No. of Mismatches)				
4(3)	5(4)	6(4)	7(5)	8(5)
gatt	tagta	gattag	gtaaaat	atgagtat
tgat	aaaag	agagtt	aaaagga	aggaagtg
taga	agggg	agttga	aaggaag	agggtaga
tttg	ggtaa	gagatt	aattttt	agttgaag
gtaa	gtatt	gttggt	ggaggtg	gagatggt
agta	tttgg	tgggtg	gggtaga	gaggatag
atgt		ttagag	tgtataa	gagtgata
aaag		ttgaga	ttattgg	ggaagtga
		atgtat		ggatagat
				gtaatatg
				gttgggaa
				tatagttg
				tattagga
				tgtgttat
				ttatgagt
				ttgttgag

The length of oligonucleotide tags in a repertoire may vary widely depending on several factors, including the size or complexity of the repertoire desired, the difficulty in synthesizing

15 corresponding tag complements on solid phase supports, the particular application, and the like. Generally, longer oligonucleotide tags permit the generation of larger repertoires; however, reliable synthesis of tag complements that exceed 40-50 nucleotides becomes increasingly difficult and monitoring and/or exercising quality control of mixtures of oligonucleotides becomes increasingly

20 difficult as complexity increases. Thus, selection of particular tag lengths and complexities requires design tradeoffs by a practitioner of ordinary skill. Preferably, oligonucleotide tags of the

invention are in the range of from 18 to 60 nucleotides in length. More preferably, oligonucleotide tags are in the range of from 18 to 40 nucleotides in length.


Preferably, minimally cross-hybridizing sets comprise words that make approximately equivalent contributions to duplex stability as every other word in the set. In this way, the stability of perfectly matched duplexes between every word and its complement is approximately equal. Guidance for selecting such sets is provided by published techniques for selecting optimal PCR primers and calculating duplex stabilities, e.g. Rychlik et al, Nucleic Acids Research, 17: 8543-8551 (1989) and 18: 6409-6412 (1990); Breslauer et al, Proc. Natl. Acad. Sci., 83: 3746-3750 (1986); Wetmur, Crit. Rev. Biochem. Mol. Biol., 26: 227-259 (1991); and the like. For shorter tags, e.g. about 30 nucleotides or less, the algorithm described by Rychlik and Wetmur is preferred, and for longer tags, e.g. about 30-35 nucleotides or greater, an algorithm disclosed by Suggs et al, pages 683-693 in Brown, editor, ICN-UCLA Symp. Dev. Biol., Vol. 23 (Academic Press, New York, 1981) may be conveniently employed. Clearly, there are many approaches available to one skilled in the art for designing sets of minimally cross-hybridizing words within the scope of the invention. For example, to minimize the effects of different base-stacking energies of terminal nucleotides when words are assembled, words may be provided that have the same terminal nucleotides. In this way, when subunits are linked, the sum of the base-stacking energies of all the adjoining terminal nucleotides will be the same, thereby reducing or eliminating variability in tag melting temperatures.

For use with the invention, words or sub-assemblies of words are initially synthesized as single stranded oligonucleotides using conventional solid phase synthetic methods, e.g. using a commercial DNA synthesizer, such as PE Applied Biosystems (Foster City, CA) model 392 DNA synthesizer, or like instrument. Preferably, the words or sub-assemblies of words are synthesized within a longer oligonucleotide having appropriate restriction endonuclease recognition sites and primer binding sites to facilitate later manipulation. Preferably, such chemically synthesized oligonucleotides are rendered double stranded by providing a primer which binds to one end of the oligonucleotides and which is extended the length of the oligonucleotides with a DNA polymerase in the presence of the four dNTPs. For example, in a preferred embodiment the following oligonucleotide (shown in the 5'→3' orientation) containing two words may be synthesized chemically (SEQ ID NO: 1):

each of such fragments comprising increasingly larger oligonucleotide precursors. Examples of both approaches are illustrated in Figures 1a (stepwise additions) and 1b (convergent assembly). In Figure 1a, vector (100) is prepared for each sequence of words "-w₁-w₂". The presence of two words in this example is only for purposes of illustration. In this embodiment, any number of words can be used. The practical constraint is the requirement that vector (100) be prepared for every sequence of words. Thus, if three four-base words of Table I are employed, then 512 (=8x64) vectors must be prepared and their sequences confirmed.

Adjacent to words (108) are cleavage sites (107) and (109) of type II's restriction endonucleases, r₂ and r₃, recognizing sites (106) and (110), respectively. Adjacent to, and upstream of, restriction site (106) is restriction site (104) recognized by restriction endonuclease, r₁. Flanking the entire assembly of restriction sites and words are optional primer binding sites (102) and (112), which may be used to copy the oligonucleotide tag for insertion into a vector as taught by Brenner et al, International application pct/us96/09513.

In the preferred embodiment of Figure 1a, vector (100) serves (114) as a starting material for the tag assembly process, i.e. at the start of the process, i=1 in the subscript of insert (120). Note that the process entails the successive insertion of the following element, or cassette:




where "w" is a word, "N" is a nucleotide, and k is an integer equal to 1, 2, 3, or 4. The term "(N)_k" is equivalent to element (109) of Figure 1a. As described above, preferably k is equal to 1 or 2, which is the length of the protruding strand resulting from cleavage with the preferred type II's restriction endonucleases of the invention. r₃ is virtually any type II's restriction endonuclease which allows a predictable sequence (109) to be engineered into vector (100). Exemplary r₃'s include Alw I, Bbs I, Bbv I, Bci VI, Bpm I, Bsa MI, Bse GI, Bsr DI, Ear I, Fau I, Mbo II, and the like. Preferably, r₃ leaves a 1 or 2 nucleotide protruding strand after cleavage. Likewise, r₂ is virtually any type II's restriction endonuclease which allows a predictable sequence (107) to be engineered into vector (100). r₂ may be selected from the same group of type II's restriction endonucleases as r₃, but preferably for a given vector r₁ and r₂ are different.

Cycles of word addition in the preferred embodiment, illustrated in Figure 1a, begin with the step of cleaving (122) vector (121) with r₁ and r₂, to remove segment (123), thereby leaving opened vector (124), which is then isolated using conventional protocols. In this embodiment, r₂ cleaves the oligonucleotide tag precursor at the upstream-most word of the tag. Separately, restriction endonucleases r₁ and r₃ recognizing restriction sites (104) and (110), respectively, are used to cleave (116) vector (100) to produce fragment (118), which is inserted (126) into opened

vector (124) to form vector (128), thereby elongating the oligonucleotide tag precursors by two words. The cycles are repeated (130) until an oligonucleotide tag repertoire of the desired length is obtained. At such point, the oligonucleotide tags may be excised from vector (128) by digesting with r_2 and r_3 .

Alternatively, repertoires may be synthesized in accordance with the invention with a convergent strategy as illustrated in Figure 1b. Vector (150), which may be identical to vector (100), contains the following elements: restriction site (152) for restriction endonuclease, r_1 , restriction site (154) for restriction endonuclease r_2 , which has cleavage site (155), one or more words (156), and restriction site (158), which has cleavage site (157). Optionally, vector (150) may also contain flanking primer binding sites as with vector (100) (not shown) for producing copies of the oligonucleotide tags or their precursors. Two aliquots (160) and (162) are taken of vector (150). In aliquot (160), vector (150) is digested with r_1 and r_2 so that fragment (161) is excised and opened vector (166) is formed. Separately, in aliquot (162), vector (150) is digested with r_1 and r_3 so that 2-word fragment (164) is excised. After purification, 2-word fragment (164) is inserted and ligated (168) into opened vector (166) to form vector (170), which contains oligonucleotide tag precursors consisting of four words each. These steps are repeated using vector (170) as the starting material. That is, two aliquots (174) and (176) are taken of vector (170). In aliquot (174), vector (170) is digested with r_1 and r_2 so that fragment (175) is excised and opened vector (180) is formed. Separately, in aliquot (176), vector (170) is digested with r_1 and r_3 so that 4-word fragment (178) is excised. After purification, 4-word fragment (178) is ligated (182) into opened vector (184) to form vector (184), which contains oligonucleotide tag precursors consisting of eight words each. Additional cycles may be carried out, or if the desired length of the tags is 8 words, then the oligonucleotide tags may be excised (186) by digesting with r_2 and r_3 .

Repertoires of oligonucleotide tags may also be produced in accordance with the invention by repeated additions of words with self-selection during the ligation step. In this embodiment, the length of the protruding strand produced by cleavage with a type II's restriction endonuclease is the same as the length of a word. When an oligonucleotide tag precursor is cleaved at a word, cleavage occurs precisely at the upstream and downstream boundaries of a word, i.e. across a word, as shown below:



where the segments "-xxxx-" represent words consisting of four nucleotides each. Preferably, in this embodiment, word lengths of either 3, 4, or 5 nucleotides are employed. A preferred implementation of this embodiment is illustrated in Figure 2. Vector (200), produced from conventional starting materials, includes the following elements: restriction site for r_4 (204), restriction site for r_5 (206), restriction site for r_6 (208), cleavage site (209), a plurality of words (210), restriction site for r_7 (212), and a restriction site for r_8 (214). As with vector (100), the above series of elements may be flanked by optional primer binding sites (202) and (216) so that the oligonucleotide tag precursors may be conveniently replicated, e.g. by PCR amplification.

Vector (221), which may be a sample of starting vector (200) or a previously processed vector, is cleaved (224) with r_4 and r_6 to produce fragment (225) and opened vector (228), which is isolated using conventional protocols. r_6 is a type II's restriction endonuclease which cleave across the upstream-most word of the oligonucleotide tag precursor of vector (228). Vector (228) is actually a mixture by virtue of the different oligonucleotide tag precursors. In particular, the protruding strand of end (226) is present in N different sequences, where N is the number of words in the minimally cross-hybridizing set being used. Separately, a sample of vector (200) is cleaved (222) with r_4 and r_8 to produce fragment (218), which is isolated. Fragment (218) is a mixture containing N^2 components in this example, where again N is the number of words in the minimally cross-hybridizing set being used. N is to the second power because the fragment contains all possible combinations of two consecutive words. Element (220) of fragment (218) is the single-stranded form of the second, or downstream-most, word of vector (200). Fragment (218) is combined with opened vector (228) under conditions that permit the single stranded forms of the words (220) and (226) to form perfectly matched duplexes. Because of the minimally cross-hybridization property of the protruding strands, these conditions are readily met. Strands that are not complementary or that contain failure sequences will not form perfectly matched duplexes and

will not be ligated. In this sense, the words in the protruding strands are "self-selecting." After insertion and ligation (230), vector (232) is formed which contains and elongated oligonucleotide tag precursor. The cleavage and insertion steps are repeated (234) until an oligonucleotide tag of the desired length is obtained, after which the oligonucleotide tag repertoire may be excised by cleaving with r₇ and r₅.

The following examples serve to illustrate the present invention and are not meant to be limiting. Selection of many of the reagents, e.g. enzymes, vectors, and other materials; selection of reaction conditions and protocols; and material specifications, e.g. word length and composition, tag length, repertoire complexity, and the like, are matters of design choice which may be made by one of ordinary skill in the art. Extensive guidance is available in the literature for applying particular protocols for a wide variety of design choices made in accordance with the invention, e.g. Sambrook et al, Molecular Cloning, Second Edition (Cold Spring Harbor Laboratory, New York, 1989); Ausubel et al, editors, Current Protocols in Molecular Biology (John Wiley & Sons, New York, 1997); and the like.

Example 1

Repertoire Synthesis by Repeated Cycles of Cleavage.

Self-Selection, Ligation, and Amplification

In this example, an oligonucleotide tag repertoire is produced such that each oligonucleotide tag consists of eight words of four nucleotides. The procedure outlined in Figure 2 is followed. A vector, corresponding to vector (200), is constructed by first inserting the following oligonucleotide (SEQ ID NO: 4) into a Bam HI and Eco RI digested pUC19:

	Pac I		Bse RI	Bsp 120		Bbs I	Eco RI	Bam HI
	↓		↓	↓		↓	↓	↓
	aattg tt aattaaggatgagctcactcctcgggcccgcataagtcttcgaattcg							
	caattaattcctactcgagtgaggagcccgggcgtattcagaagcttaagcctag							

Formula II

Separately, the oligonucleotide of Formula I and forward and reverse primers (SEQ ID NO: 2 and SEQ ID NO: 3) are synthesized using a conventional DNA synthesizer, e.g. PE Applied Biosystems (Foster City, CA) model 392. The oligonucleotide of Formula I is a mixture

gaggagatgaagacga-word
acgtctcctctacttctgct-wordword

5 This fragment is inserted into the above vector opened by digestion with Bbs I and Pst I to give the following construct (SEQ ID NO: 8):

...gcagaggagatgaagacga-wordwordword-gggcccaatgctgcaagcttggcg...
...cgtctcctctacttctgct-wordwordword-cccgggttacgacggttcgaaccgc...

10

which contains an oligonucleotide tag precursor of three words. The steps of cleaving, inserting, and amplification are repeated until a construct containing eight words is obtained. Preferably, at each step, reactants, e.g. vectors and/or inserts, are provided in amounts that are at least ten times the complexity of the reactant. When synthesis is complete, the eight-word construct is cleaved

15 with Bse RI and Bsp 120 and the following fragment containing the oligonucleotide tag repertoire is isolated:

(word)₈g
ct (word)₈cccgg

20

The isolated fragment is then inserted into the Bse RI/Bsp 120 vector of Formula II, which vector is used to transform a suitable host. The construct is ready for inserting polynucleotides, such as cDNAs, into the Eco RI restriction site to form tag-polynucleotide conjugates in accordance with the method of Brenner et al, International patent application pct/us96/09513.

25

Example 2

Repertoire Synthesis by Convergent Assembly of Error-free Oligonucleotide Tag Precursors

In this example, an oligonucleotide tag repertoire is produced following the procedure

30 outlined in Figure 1b. Each oligonucleotide tag consists of eight words of six nucleotides each (selected from those listed in Table I) to give the repertoire having an expected complexity of 9^8 , or about 4.3×10^7 . For each of the $9 \times 9 = 81$ two-word combinations, an oligonucleotide (SEQ ID NO: 9) of the following form is synthesized:

35

which is isolated. The vectors in the other part are cleaved with Pst I and Bse RI and the linearized word-containing vectors are isolated. The word-containing fragments are ligated into the linearized vectors to form the following construct (SEQ ID NO: 12):

```

5  ... ctgcagttatcggaggagatgaagacgg[word][word]gg[word][word]-
   ... gacgtcaatagcctcctctacttctgcc[word][word]cc[word][word]-

                                     -gggcccatatatccgtctgcacaagcttggcg ...
10                                     -cccggtatataggcagacgtgttcgaaccgc ...

```

After cloning, the construct is again divided into two parts and the steps are repeated to give the final 8-word repertoire having the form:

```

15  .. gaagacgg([word][word]gg)4gccc ...
   .. cttctgcc([word][word]cc)4cggg ...

```

This may then be cleaved with Bse RI and Bsg I and re-cloned into a vector similar to that of Formula II for attachment to polynucleotides.

Example 3

Construction of an Eight-Word Tag Library

In this example, an eight-word tag library with four-nucleotide words was constructed from two two-word libraries in vectors pLCV-2 and pUCSE-2. Prior to construction of the eight-word tag library, 64 two-word double stranded oligonucleotides were separately inserted into pUC19 vectors and propagated. These 64 oligonucleotides consisted of every possible two-word pair made up of four-nucleotide word selected from an eight-word minimally cross-hybridizing set described in Brenner, U.S. patent 5,604,097. After the identities of the inserts were confirmed by sequencing, the inserts were then amplified by PCR and equal amounts of each amplicon were combined to form the inserts of the two-word libraries in vectors, pLCV-2 and pUCSE-2. These were then used as described below to form an eight-word tag library in pUCSE, after which the eight-word insert was transferred to vector pNCV3 which contains additional primer binding sites and restriction sites to facilitate tagging and sorting polynucleotide fragments.

A. Construction of two-word sequences in pUCSE.

pUC19 was digested to completion with Sap I and Eco RI using the manufacturer's protocol and the large fragment was isolated. All restriction endonucleases unless otherwise noted

were purchased from New England Biolabs (Beverly, MA). The small Sap I-Eco RI fragment was removed to eliminate the β -gal promoter sequence, which was found to skew the representation of some combinations of words in the final library. The following adaptor (SEQ ID NO: 13) was ligated to the isolated large fragment in a conventional ligation reaction to give plasmid pUCSE as a ligation product.

10

Eco RI	Pst I	Eco RV	Hind III
↓	↓	↓	↓
aattctagactgcagttgatatcttaagctt			
gatctgacgtcaactatagaattcgaacga			

A bacterial host was transformed by the ligation product using electroporation, after which the transformed bacteria were plated, a clone was selected, and the insert of its plasmid was sequenced for confirmation. pUCSE isolated from the clone was then digested with Eco RI and Hind III using the manufacturer's protocol and the large fragment was isolated. The following adaptor (SEQ ID NO: 14) was ligated to the large fragment to give plasmid pUCSE-D1 which contained the first di-word (underlined).

20

EcoRI	PstI	BseRI	BbsI	Bsp120I	HindIII
↓	↓	↓	↓	↓	↓
aattctgcagaggagatgaagacgaaaagaaaggggcccacatgctgca					
gacgtctcctctacttctgct <u>tttctttcccggtacgacgttcga</u>					
					↑
					BbvI

30 Formula I

Further plasmids, pUCSE-D2 through pUCSE-D64, containing di-words were separately constructed from pUCSE-D1 by digesting it with Pst I and Bsp120 I and separately ligating the following adaptors (SEQ ID NO: 15) to the large fragment.

35

gaggagatgaagacga	[word]	[word]	g
acgtctcctctacttctgct	[word]	[word]	cccgg

Formula II

The words of the top strand were selected from the following minimally cross-hybridizing set: gatt, tgat, taga, ttg, gtaa, agta, atgt, and aaag. After cloning and isolation, the inserts of the vectors were sequenced to confirm the identities of the di-words.

5

B. Construction pLCV.

Plasmid cloning vector pLCV-D1 was created from plasmid vector pBC.SK⁺ (Stratagene) as follows, using the following oligonucleotides:

10 S-723 (SEQ ID NO:16)

5'-CGA GAA AGA GGG ATA AGG CTC GAG CTT AAT TAA GAG TCG ACG AAT
TCG GGC CCG GAT CCT GAC TCT TTC TCC CT-3'

S-724 (SEQ ID NO:17)

15 5'-CTA GAG GGA GAA AGA GTC AGG ATC CGG GCC CGA ATT CGT CGA CTC
TTA ATT AAG CTC GAG CCT TAT CCC TCT TTC TCG GTA C-3'

S-785 (SEQ ID NO:18)

20 5'-TCG AGG CAT AAG TCT TCG AAT TCC ATC ACA CTG GGA AGA CAA CGT
AG-3'

S-786 (SEQ ID NO:19)

25 5'-GAT CCT ACG TTG TCT TCC CAG TGT GAT GGA ATT CGA AGA CTT ATG
CC-3'

S-960 (SEQ ID NO:20)

5'-TCG ATT AAT TAA CAA GCT TTG GGC CCT CGA GCA TAA GTC TTC TGC
AGA ATT CGG ATC CAT CGA TGG TCA TAG C-3'

30 S-961 (SEQ ID NO:21)

5'-TGT TTC CTG CCA CAC AAC ATA CGA GCC GGA AGC GGC CGC TCT AGA-3'

S-962 (SEQ ID NO:22)

35 5'-AGC GTC TAG AGC GGC CGC TTC CGG CTC GTA TGT TGT GTG GCA GGA
AAC AGC TAT GAC CAT C-3'

S-963 (SEQ ID NO:23)

5' -GAT GGA TCC GAA TTC TGC AGA AGA CTT ATG CTC GAG GGC CCA AAG
CTT GTT AAT TAA-3'

5

S-1105 (SEQ ID NO:24)

5' -TCGA GGG CCC GCA TAA GTC TTC-3'

S-1106 (SEQ ID NO:25)

10 5' -TCGA GAA GAC TTA TGC GGG CCC-3'

Oligonucleotides S-723 and S-724 were kinased, annealed together, and ligated to pBC.SK⁻ which had been digested with Kp^rI and Xba^I and treated with calf intestinal alkaline phosphatase, to create plasmid pSW143.1.

15 Oligonucleotides S-785 and S-786 were kinased, annealed together, and ligated to plasmid pSW143.1, which had been digested with Xho^I and Bam^HI and treated with calf intestinal alkaline phosphatase, to create plasmid pSW164.02.

Oligonucleotides S-960, S-961, S-962, and S-963 were kinased and annealed together to form a duplex consisting of the four oligonucleotides. Plasmid pSW164.02 was digested with Xho^I and Sap^I. The digested DNA was electrophoresed in an agarose gel, and the approximately 3045 bp product was purified from the appropriate gel slice. Plasmid pUC4K (from Pharmacia) was digested with Pst^I and electrophoresed in an agarose gel. The approx. 1240 bp product was purified from the appropriate gel slice. The two plasmid products (from pSW164.02 and pUC4K) were ligated together with the S-960/961/962/963 duplex to create plasmid pLCVa.

25 DNA from Adenovirus5 (New England Biolabs) was digested with Pac^I and Bsp¹20^I, treated with calf intestinal alkaline phosphatase, and electrophoresed in an agarose gel. The approx. 2853 bp product was purified from the appropriate gel slice. This fragment was ligated to plasmid pLCVa which had been digested with Pac^I and Bsp¹20^I, to create plasmid pSW208.14.

Plasmid pSW208.14 was digested with Xho^I, treated with calf intestinal alkaline phosphatase, and electrophoresed in an agarose gel. The approx. 5374 bp product was purified from the appropriate gel slice. This fragment was ligated to oligonucleotides S-1105 and S-1106 (which had been kinased and annealed together) to produce plasmid pLCVb, which was then digested with Eco^RI and Hind^{III}. The large fragment was isolated and ligated to the Formula I adaptor (SEQ ID NO: 14) to give pLCV-D1.

As above for pUCSE, further plasmids, pLCV-D2 through pLCV-D64, containing di-words were separately constructed from pLCV-D1 by digesting it with Pst I and Bsp120 I, isolating the large fragment, and a ligating an adaptor of Formula II. After cloning and isolation, the inserts of the vectors were sequenced to confirm thhe identities of the di-words

5

C. Construction of two-word libraries, pUCSE-2 and pLCV-2.

Each of the vectors pLCV-D1 through -D64 and pUCSE-D1 through -D64 was separately amplified by PCR. The components of the reaction mixture were as follows:

10	10 µl	template (about 1-5 ng)
	10 µl	10x Klentaq™ buffer (Clontech Laboratories, Palo Alto, CA)
	2.5 µl	biotinylated DF primer at 100 pmoles/µl
	2.5 µl	biotinylated DR primer at 100 pmoles/µl
	2.5 µl	10 mM deoxynucleoside triphosphates
15	5 µl	DMSO
	66.5 µl	H ₂ O
	1 µl	Advantage Klentaq™ (Clontech Laboratories, Palo Alto, CA)

The temperature of the reactions was controlled as follows: 94°C for 3 min; 25 cycles of 94°C for 30 sec, 60°C for 30 sec, and 72°C for 10 sec; followed by 72°C for 3 min, then 4°C. The DF and DR primer binding sites were upstream and downstream portions of the vectors selected to give amplicons of 104 basepairs in length. After the reactions were completed, 5 µl of each PCR product were separated polyacrylamide gel electrophoresis (20% with 1xTBE) to confirm by visual inspection that the reaction yields were approximately the same for each PCR. After such confirmation, using conventional protocols, 10 µl of each PCR was extracted twice with phenol and once with chloroform, after which the DNA in the aqueous phase was precipitate with ethanol. After resuspension in 200 µl of 1x NEB buffer #2 (New England Biolabs, Beverly, MA), the DNA was cleaved with Bbv I and Eco RI by adding the enzymes in 50 µl of the manufacturer's recommended buffer. The digestion resulted in the production of three fragments: a biotinylated fragment of 38 basepairs, a di-word-containing fragment of 29 basepairs, and a biotinylated fragment of 37 basepairs. After completion of the reaction, the excess biotinylated primers were removed by adding 50 µl 50% Ultralink (streptavidin-Sepharose, Pierce Chemical Co., Rockford, IL) and vortexing the mixture at room temperature for 30 min. The Ultralink material was separated from the reaction mixture by centrifugation, after which approximately half of the mixture was separated by polyacrylamide gel electrophoresis (20% gel). The 29-basepair band was cut out of the gel and the 29-basepair fragment was eluted using the "crush and soak" method, e.g. Sambrook et al, Molecular Cloning, Second Edition (Cold Spring Harbor Laboratory, New

York, 1989). This material was then ligated into either pLCV-D1 or pUCSE-D1 after the latter were digested with Bbs I and Eco RI and treated with calf intestine alkaline phosphatase, using manufacturer's recommend protocols.

5 D. Construction of pNCV3.

pNCV3 was constructed by first assembling the following fragment (SEQ ID NO: 26) from synthetic oligonucleotides:

```

10  EcoRI
    ↓
    aattctgtaaaacgacggccagtcgccagggttttcccagtcacgacgtgaataaatag-
      gacattttgctgccggtcagcgggtcccaaaagggtcagtgctgcacttattttatc-

15

    PacI                               Bsp120I
    ↓                                 ↓
    ttaattaaggaataggcctctcctcgagctcggtagccgggcccgcataagtcttc-
20  aattaattccttatccggagaggagctcgagccatggcccgggcgtattcagaag-

25      ClaI           EcoRV       SapI       BamHI
      ↓             ↓           ↓           ↓
    atctatcgatgattgaagagcgatatcgctcttcaatcggatccatcc-
    tagatagctactaacttctcgctatagcgagaagttagcctaggtagg-

30              ↑
              SapI

                                HindIII
                                ↓
    tcaactaattaccacacaacatacgagccggaagcgggtcatagctgtttcctga
35  agttgattaatggtgtgttgatgctcggccttcgcccagtatcgacaaaggacttcga
  
```

After isolation, the fragment was cloned into Eco RI and Hind III-digested pLCV-D1 using conventional protocols.

40 E. Assembly of eight-word library.

The di-words of pLCV-2 were amplified either by PCR or plasmid expansion, the product was digested with Eco RI and BbvI after which the Eco RI-BbvI fragment was isolated as insert 1.

Two-word library pUCSE-2 was digested with Eco RI, Bbs I, and Pst I, after which the large fragment was treated with calf intestine alkaline phosphatase to give vector 1. Vector 1 and insert 1 were combined in a conventional ligation reaction to give three-word library, pUCSE-3. pUCSE-3 was digested with Eco RI, Bbs I, and Pst I, after which the large fragment was treated with calf intestine alkaline phosphatase to give vector 2. Vector 2 and insert 1 were then combined in a conventional ligation reaction to give four-word library, pUCSE-4. The 4-mer words of pUCSE-4 were amplified either by PCR or plasmid expansion, the product was digested with Eco RI and BbvI after which the Eco RI-BbvI fragment was isolated as insert 2. pLCV-2 was digested with Eco RI, Bbs I, and Pst I, after which the large fragment was treated with calf intestine alkaline phosphatase to give vector 3. Vector 3 and insert 2 were then combined in a conventional ligation reaction to give five-word library, pLCV-5. The 5-mer words of pLCV-5 were amplified either by PCR or plasmid expansion, the product was digested with Eco RI and BbvI after which the Eco RI-BbvI fragment was isolated as insert 3. pUCSE-4 was digested with Eco RI, Bbs I, and Pst I, after which the large fragment was treated with calf intestine alkaline phosphatase to give vector 4. Vector 4 and insert 3 were then combined in a conventional ligation reaction to give eight-word library, pUCSE-8. The 8-mer words of pUCSE-8 were amplified either by PCR or plasmid expansion, the product was digested with Bse RI and Bsp120 I, after which the BseRI-Bsp120I fragment was isolated as insert 4. pNCV3 was digested with Bse RI, Bsp120 I, and Sac I, after which the large fragment was isolated and treated with calf intestine alkaline phosphatase to give vector 5. Vector 5 was then combined with insert 4 in a conventional ligation reaction to give the eight-word library pNCV3-8.

F. Confirmation Sequencing of a Random Selection of Eight-Word Tags.

The results of the word assembly were tested by sequencing the 8-word inserts of 176 vectors from the pNCV3-8 library. The results of the sequence determinations are summarized in the following table:

Number of Tags	Result	Percentage
147	Perfect 8 words	83.5%
11	Perfect 7 words	6.2%
8	No insert	4.5%
4	8 words with 1 base deletion	2.2%
3	8 words with an incorrect word	1.7%
1	12 words	0.5%
1	10 words	0.5%
1	9 words	0.5%

Sequence Listing

<110> Brenner, Sydney
 Williams, Steven R.
 <120> Enzymatic synthesis of oligonucleotide tags
 <130> 810-02
 <140>
 <141>
 <150>
 <151>
 <160> 26
 <170> Microsoft Word97

<210> 1
 <211> 58
 <212> DNA
 <213> Artificial Sequence
 <220> No special biological significance.
 <221>
 <222>
 <223>
 <400> 1
 cgacacctgc agaggagatg aagacgaddd ddddggggcc catgctgcaa 50
 gcttaccg 58

<210> 2
 <211> 17
 <212> DNA
 <213> Artificial Sequence
 <220> No special biological significance.
 <221> Primer.
 <222> n.a.
 <223>
 <400> 2
 cgacacctgc agaggag 17

<210> 3
 <211> 17
 <212> DNA
 <213> Artificial Sequence
 <220> No special biological significance.
 <221> Primer.
 <222> n.a.
 <223>
 <400> 3
 cggttaagctt gcagcat 17

<210> 4
 <211> 55
 <212> DNA
 <213> Artificial Sequence
 <220> No special biological significance.
 <221> Adaptor.
 <222> n.a.
 <223>
 <400> 4
 aattgttaat taaggatgag ctcaactctc gggcccgcat aagtcttcga 50

attcg 55

<210> 5
 <211> 57
 <212> DNA
 <213> Artificial Sequence
 <220> No special biological significance.
 <221> Cloning vector.
 <222> n.a.
 <223>
 <400> 5
 cgacctgcag aggagatgaa gacgaddddd dddgggcccc atgctgcaag 50
 cttggcg 57

<210> 6
 <211> 32
 <212> DNA
 <213> Artificial Sequence
 <220> No special biological significance.
 <221> Vector.
 <222>
 <223>
 <400> 6
 dddddddgg gcccaatgct gcaagcttgg cg 32

<210> 7
 <211> 20
 <212> DNA
 <213> Artificial Sequence
 <220> No special biological significance.
 <221> Adaptor.
 <222> n.a.
 <223> Preferably, contains fluorescent label.
 <400> 7
 gaggagatga agacgadddd 20

<210> 8
 <211> 55
 <212> DNA
 <213> Artificial Sequence
 <220> No special biological significance.
 <221> Vector.
 <222> n.a.
 <223>
 <400> 8
 gcagaggaga tgaagacgad dddddddddd dgggccaat gctgcaagct 50
 tggcg 55

<210> 9
 <211> 78
 <212> DNA
 <213> Artificial Sequence
 <220> No special biological significance.
 <221> Tag repertoire.
 <222> n.a.
 <223> n.a.
 <400> 9

cgacacctgc agttatcgga ggagatgaag acggdddddd dddddgggc 50
ccatatatcc gtctgcacaa gttaccg 78

<210> 10
<211> 72
<212> DNA
<213> Artificial Sequence
<220> No special biological significance.
<221> Vector.
<222> N.a.
<223> N.a.
<400> 10

ctgcagttat cggaggagat gaagacggdd dddddddddd gggcccatat 50
atccgtctgc acaagcttac cg 72

<210> 11
<211> 36
<212> DNA
<213> Artificial Sequence
<220> No special biological significance.
<221> Adaptor.
<222> N.a.
<223> N.a.
<400> 11

gttatcggag gagatgaagac ggddddddddd ddddgg 36

<210> 12
<211> 86
<212> DNA
<213> Artificial Sequence
<220> No special biological significance.
<221> Vector.
<222> N.a.
<223> N.a.
<400> 12

ctgcagttat cggaggagat gaagacggdd dddddddddd ggddddddddd 50
ddddggggccc atatatccgt ctgcacaagc ttaccg 86

<210> 13
<211> 31
<212> DNA
<213> Artificial Sequence
<220> No special biological significance.
<221> Adaptor.
<222> N.a.
<223> N.a.
<400> 13

aattctagac tgcagttgat atcttaagct t 31

<210> 14
<211> 47
<212> DNA
<213> Artificial Sequence
<220> No special biological significance.
<221> Adaptor.
<222> N.a.

<223> N.a.
 <400> 14
 aattctgcag aggagatgaa gacgaaaaga aaggggcca tgctgca 47

<210> 15
 <211> 25
 <212> DNA
 <213> Artificial Sequence
 <220> No special biological significance.
 <221> Adaptor.
 <222> N.a.
 <223> N.a.
 <400> 15
 gaggagatga agacgadddd ddddg 25

<210> 16
 <211> 74
 <212> DNA
 <213> Artificial Sequence
 <220> No special biological significance.
 <221> Oligonucleotide.
 <222> N.a.
 <223> N.a.
 <400> 16
 cgagaaagag ggataaggct cgagcttaat taagagtcga cgaattcggg 50
 cccggtatcct gactctttct ccct 74

<210> 17
 <211> 82
 <212> DNA
 <213> Artificial Sequence
 <220> No special biological significance.
 <221> Oligonucleotide.
 <222> N.a.
 <223> N.a.
 <400> 17
 ctagaggag aaagagtcag gatccggggc cgaattcgtc gactcttaat 50
 taagctcgag ccttatccct cttctcggg ac 82

<210> 18
 <211> 47
 <212> DNA
 <213> Artificial Sequence
 <220> No special biological significance.
 <221> Oligonucleotide.
 <222> N.a.
 <223> N.a.
 <400> 18
 tcgaggcata agtcttcgaa ttccatcaca ctgggaagac aacgtag 47

<210> 19
 <211> 47

<212> DNA
 <213> Artificial Sequence
 <220> No special biological significance.
 <221> Vector.
 <222> N.a.
 <223> N.a.
 <400> 19
 gatcctacgt tgtcttccca gtgtgatgga attcgaagac ttatgcc 47

<210> 20
 <211> 72
 <212> DNA
 <213> Artificial Sequence
 <220> No special biological significance.
 <221> Oligonucleotide.
 <222> N.a.
 <223> N.a.
 <400> 20
 tcgattaatt aacaagcttt gggccctcga gcataagtct tctgcagaat 50
 tcggatccat cgatggtcac ag 72

<210> 21
 <211> 45
 <212> DNA
 <213> Artificial Sequence
 <220> No special biological significance.
 <221> Oligonucleotide.
 <222> N.a.
 <223> N.a.
 <400> 21
 tgtttctctgc cacacaacat acgagccgga agcggccgct ctaga 45

<210> 22
 <211> 62
 <212> DNA
 <213> Artificial Sequence
 <220> No special biological significance.
 <221> Oligonucleotide.
 <222> N.a.
 <223> N.a.
 <400> 22
 agcgtctaga gcggccgctt ccggctcgta tggtgtgtgg caggaaacaa 50
 gctatgacca tc 62

<210> 23
 <211> 57
 <212> DNA
 <213> Artificial Sequence
 <220> No special biological significance.
 <221> Oligonucleotide.
 <222> N.a.
 <223> N.a.
 <400> 23

gatggatccg aattctgcag aagacttatg ctcgagggcc caaagcttgt	50
taattaa	57

<210> 24	
<211> 22	
<212> DNA	
<213> Artificial Sequence	
<220> No special biological significance.	
<221> Oligonucleotide.	
<222> N.a.	
<223> N.a.	
<400> 24	
tcgagggccc gcataagtct tc	22

<210> 25	
<211> 22	
<212> DNA	
<213> Artificial Sequence	
<220> No special biological significance.	
<221> Vector.	
<222> N.a.	
<223> N.a.	
<400> 25	
tcgagaagac ttatgcgggc cc	22

<210> 26	
<211> 217	
<212> DNA	
<213> Artificial Sequence	
<220> No special biological significance.	
<221> Adaptor.	
<222> N.a.	
<223> N.a.	
<400> 26	
aattctgtaa aacgacggcc agtcgccagg gttttcccag tcacgacgtg	50
aataaatagt taattaagga ataggcctct cctcgagctc ggtaccgggc	100
ccgcataagt cttcatctat cgatgattga agagcgatat cgctcttcaa	150
tcggatccat cctcaactaa ttaccacaca acatacgagc cggaagcggg	200
tcatagctgt ttctga	217